Presentation is loading. Please wait.

Presentation is loading. Please wait.

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Published byElfrieda Terry Modified over 6 years ago

Similar presentations

Presentation on theme: "Emerging Frontline Treatments for Patients With Hodgkin Lymphoma"— Presentation transcript:

1 Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

2

3 Hodgkin Lymphoma Rare, But Highly Curable

4 ABVD Safety Profile Adverse Effects Are Tolerable

5 Stanford V vs ABVD Stanford V: Comparable Efficacy, More Toxicity

6 BEACOPP vs ABVD BEACOPP: Comparable OS, But More Toxic

7 Goals of New Therapies for Hodgkin Lymphoma

8 RATHL Trial PET-CT as a Measure of Early Response to Chemotherapy

9 RATHL Trial Results Bleomycin Not Necessary

10 New Therapies for Hodgkin Lymphoma Are Needed

11 Brentuximab Vedotin: Anti-CD30 Monoclonal Antibody

12 Phase 1 Trial of Brentuximab Vedotin in Patients With Relapsed Hodgkin Lymphoma After ASCT

13 Phase 2 Trial of Brentuximab Vedotin in Patients With Hodgkin Lymphoma After Relapse from ASCT

14 Reduction in Tumor Measurement

15 Secondary Endpoints: OS and PFS

16 Brentuximab Vedotin: Safety Profile Different From Chemotherapy Profiles

17 Phase 1 Trials: Brentuximab Vedotin + ABVD vs AVD in Patients With Newly Diagnosed Hodgkin Lymphoma

18 Phase 3 Trial: ECHELON-1 Brentuximab Vedotin + AVD (A + AVD) Vs AVBD As Frontline Therapy

19 Phase 1/2 Trial: Frontline Brentuximab Vedotin in Patients 60 Years and Older

20 Simplified Concept of CTLA-4 and PD-1 Immune Checkpoints

21 Phase 1 Trials of Immune Checkpoint Inhibitors in Patients With Relapsed or Refractory Hodgkin Lymphoma Safety and Efficacy

22 Phase 2 Trial of Nivolumab in Patients With Relapsed Hodgkin Lymphoma

23 Brentuximab Vedotin and Checkpoint Inhibitors Can Potentially Be Combined

24 Concluding Remarks

25 Abbreviations

26 Abbreviations (cont)

Download ppt "Emerging Frontline Treatments for Patients With Hodgkin Lymphoma"

Similar presentations

Gopal AK et al. Proc ASH 2013;Abstract 4382.

Gopal AK et al. Proc ASH 2013;Abstract 4382.
Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.
LaCasce A et al. Proc ASH 2014;Abstract 293.

LaCasce A et al. Proc ASH 2014;Abstract 293.
Ansell SM et al. N Engl J Med 2015;372(4):311-9.

Ansell SM et al. N Engl J Med 2015;372(4):311-9.
Lesokhin AM et al. Proc ASH 2014;Abstract 291.

Lesokhin AM et al. Proc ASH 2014;Abstract 291.
Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.
Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.
A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Shustov AR et al. Proc ASH 2010;Abstract 961.

Shustov AR et al. Proc ASH 2010;Abstract 961.
Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.
Oki Y et al. Proc ASH 2013;Abstract 252.

Oki Y et al. Proc ASH 2013;Abstract 252.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.

KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
Fujiwara H et al. Proc ASH 2015;Abstract 181.

Fujiwara H et al. Proc ASH 2015;Abstract 181.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Similar presentations

Ads by Google